Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
12 mai 2022 16h20 HE
|
Processa Pharmaceuticals, Inc.
Amended Next Generation Capecitabine study has restarted which will elucidate timelines for de novo formation of DPDExpanded efforts for enrollment in PCS499PCS12852 on target to complete enrollment...